PMID- 16427030
OWN - NLM
STAT- MEDLINE
DCOM- 20060811
LR  - 20141120
IS  - 0006-3223 (Print)
IS  - 0006-3223 (Linking)
VI  - 60
IP  - 1
DP  - 2006 Jul 1
TI  - Nitrous oxide and xenon prevent amphetamine-induced carrier-mediated dopamine 
      release in a memantine-like fashion and protect against behavioral sensitization.
PG  - 49-57
AB  - BACKGROUND: Amphetamine administration induces stimulation-independent dopamine 
      release in the nucleus accumbens (NAcc) through reverse dopamine transport, a 
      critical neurochemical event involved in its psychostimulant action, and 
      furthermore decreases stimulation-dependent vesicular dopamine release. These 
      effects may involve possible indirect glutamatergic mechanisms. METHODS: We 
      investigated the effects of nitrous oxide and xenon, which possess antagonistic 
      action at the N-methyl-D-aspartate (NMDA) receptor, on brain slices ex vivo on 
      amphetamine-induced changes in carrier-mediated and KCl-evoked dopamine release 
      in the NAcc, and in vivo on amphetamine-induced locomotor sensitization. RESULTS: 
      Like the low-affinity NMDA receptor antagonist memantine, but not the 
      prototypical compound MK-801, nitrous oxide and xenon at appropriate 
      concentrations blocked both the increase in carrier-mediated dopamine release and 
      locomotor sensitization produced by amphetamine. CONCLUSIONS: In contrast to what 
      has generally been found using prototypical NMDA receptor antagonists, these data 
      regarding the effect of memantine, nitrous oxide, and xenon support the 
      hypothesis that activation of certain NMDA receptors (possibly those containing 
      the NR1a/NR2D subunit) in the NAcc is involved in the amphetamine-induced 
      increase in carrier-mediated dopamine release and the development of behavioral 
      sensitization to amphetamine. Nitrous oxide, xenon, and memantine may be of 
      therapeutic interest for treating drug dependence.
FAU - David, Helene N
AU  - David HN
AD  - NNOXe Pharmaceuticals, Quebec, Canada.
FAU - Ansseau, Marc
AU  - Ansseau M
FAU - Lemaire, Marc
AU  - Lemaire M
FAU - Abraini, Jacques H
AU  - Abraini JH
LA  - eng
PT  - Comparative Study
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20060119
PL  - United States
TA  - Biol Psychiatry
JT  - Biological psychiatry
JID - 0213264
RN  - 0 (Central Nervous System Stimulants)
RN  - 0 (Excitatory Amino Acid Antagonists)
RN  - 3H3U766W84 (Xenon)
RN  - 6LR8C1B66Q (Dizocilpine Maleate)
RN  - CK833KGX7E (Amphetamine)
RN  - K50XQU1029 (Nitrous Oxide)
RN  - VTD58H1Z2X (Dopamine)
RN  - W8O17SJF3T (Memantine)
SB  - IM
MH  - Amphetamine/*administration & dosage
MH  - Animals
MH  - Behavior, Animal/drug effects
MH  - Central Nervous System Stimulants/*administration & dosage
MH  - Dizocilpine Maleate/pharmacology
MH  - Dopamine/*metabolism
MH  - Dose-Response Relationship, Drug
MH  - Drug Interactions
MH  - Excitatory Amino Acid Antagonists/*pharmacology
MH  - In Vitro Techniques
MH  - Male
MH  - Memantine/*pharmacology
MH  - Motor Activity/*drug effects
MH  - Nitrous Oxide/*pharmacology
MH  - Nucleus Accumbens/drug effects
MH  - Rats
MH  - Rats, Sprague-Dawley
MH  - Time Factors
MH  - Xenon/*pharmacology
EDAT- 2006/01/24 09:00
MHDA- 2006/08/12 09:00
CRDT- 2006/01/24 09:00
PHST- 2005/04/27 00:00 [received]
PHST- 2005/09/27 00:00 [revised]
PHST- 2005/10/12 00:00 [accepted]
PHST- 2006/01/24 09:00 [pubmed]
PHST- 2006/08/12 09:00 [medline]
PHST- 2006/01/24 09:00 [entrez]
AID - S0006-3223(05)01272-2 [pii]
AID - 10.1016/j.biopsych.2005.10.007 [doi]
PST - ppublish
SO  - Biol Psychiatry. 2006 Jul 1;60(1):49-57. doi: 10.1016/j.biopsych.2005.10.007. 
      Epub 2006 Jan 19.